February 8, 2022 07:08 AM EST

FDA ‘re-evaluating’ approvals for TG Therapeutics’ cancer drug after finding possible increased risk of death

The FDA said late last week that due to the possible increased risk of death in patients taking TG Therapeutics’ cancer drug Ukoniq (umbralisib) in …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA ‘re-eval­u­at­ing’ ap­provals for TG Ther­a­peu­tics’ can­cer drug af­ter find­ing pos­si­ble in­creased risk of death